Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part phase Ib/II study

[img]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
491kB
[img]
Preview
PDF (Supplementary Information) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
733kB

Item Type:Letter
Title:Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part phase Ib/II study
Creators Name:Rambaldi, A. and Iurlo, A. and Vannucchi, A.M. and Noble, R. and von Bubnoff, N. and Guarini, A. and Martino, B. and Pezzutto, A. and Carli, G. and De Muro, M. and Luciani, S. and McMullin, M.F. and Cambier, N. and Marolleau, J.P. and Mesa, R.A. and Tibes, R. and Pancrazzi, A. and Gesullo, F. and Bettica, P. and Manzoni, S. and Di Tollo, S.
Keywords:Carbamates, Janus Kinase 2, Maximum Tolerated Dose, Mutation, Polycythemia Vera, Quality of Life
Source:Leukemia
ISSN:0887-6924
Publisher:Nature Publishing Group
Volume:34
Number:8
Page Range:2234-2237
Date:August 2020
Official Publication:https://doi.org/10.1038/s41375-020-0735-y
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library